Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Romania
  4. Bucharest Stock Exchange
  5. Zentiva S.A.
  6. News
  7. Summary
    SCD   ROSCDBACNOR8

ZENTIVA S.A.

(SCD)
  Report
End-of-day quote. End-of-day quote Bucharest Stock Exchange - 10/20
2.66 RON   0.00%
09/28ZENTIVA S A : Convening notice Zentiva S.A. - OGMS_01.11.2021
PU
09/28ZENTIVA S A : Memo OGMS 01.11.2021
PU
09/28ZENTIVA S A : Draft Resolution_OGMS_01.11.2021
PU
SummaryChartsNewsCompanyFinancialsConsensus 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Zentiva S A : to further invest into their Prague manufacturing site

05/21/2021 | 07:30am EDT

Prague - Zentiva, the largest supplier of medicines to the Czech patients and the Czech market, will invest a further 27 million Euros into its Flagship Prague Manufacturing facility as part of a continuing capacity expansion programme. This investment follows on from the 35 million Euros invested at the Prague site over the last three years.

'The supply of medicines is more important than ever. At Zentiva we respond to the needs of the people in Europe and beyond who trust and depend on Zentiva medicines every day. We take the responsibility to make high quality medicines affordable and accessible. By investing in our manufacturing sites, into our business and into our team we will continue our growth story', stated Safak Oner, Head of Industrial Operations.

High speed production lines have been commissioned and installed in the Prague site to respond to the accelerating demand for Zentiva medicines. 2020 saw the Prague site deliver a record 129 million packs of medicine which will be again surpassed in 2021.

Through the investments made so far Zentiva has been able to rapidly increase supply of vital medicines such as noradrenaline used in intensive care and dexamethasone used for treating Covid patients. The new investments will support the further production of cardiovascular medicines, medicines to support mental health and provide the technology base for the development new oncology value-added medicines.

Safak Oner: ' We are very proud that the heart of our business is in the Czech Republic. The strong investment programme will also help create new employment opportunities and further strengthen our contribution to the science and technology base here in Prague and across the Czech Republic.'

Zentiva is a leading supplier of high quality-affordable medicines across Europe with its headquarters in Prague.

About Zentiva

Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites - including flagship sites in Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people's daily healthcare needs.

At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on. Learn more about Zentiva.com.

Contact:

Media

Mounira Lemoui

Head of Communications

ZENTIVA GROUP, a.s.

U kabelovny 529/16

Dolni M?cholupy

102 00 Prague 10

Mobil: (+420) 727 873 159

E-mail: mounira.lemoui@zentiva.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ZENTIVA S.A.
09/28ZENTIVA S A : Convening notice Zentiva S.A. - OGMS_01.11.2021
PU
09/28ZENTIVA S A : Memo OGMS 01.11.2021
PU
09/28ZENTIVA S A : Draft Resolution_OGMS_01.11.2021
PU
09/28ZENTIVA S A : Electronic vote tutorial_OGMS_01.11.2021
PU
09/27ZENTIVA S A : - Partnership with Coursera boosts the offering after pilot in Summer
AQ
08/31ZENTIVA S A : SCD_Zentiva-Fin report 30.06.2021-EN
PU
08/31Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
06/30ZENTIVA S A : SA_EN_Non-financial report 2020_30.06.2021
PU
05/31ZENTIVA S A : Zent2U announces successful development completion of Metformin with control..
AQ
05/21ZENTIVA S A : to further invest into their Prague manufacturing site
AQ
More news
Financials
Sales 2020 558 M 131 M 131 M
Net income 2020 65,6 M 15,5 M 15,5 M
Net cash 2020 401 M 94,5 M 94,5 M
P/E ratio 2020 30,8x
Yield 2020 -
Capitalization 1 854 M 436 M 437 M
EV / Sales 2019 3,32x
EV / Sales 2020 2,90x
Nbr of Employees 782
Free-Float 4,05%
Chart ZENTIVA S.A.
Duration : Period :
Zentiva S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 2,66 RON
Average target price 3,11 RON
Spread / Average Target 16,9%
Managers and Directors
Simona Cocos General Manager & Executive Director
Claudiu-Nicolae Manolescu Chief Financial Officer
Nicholas Robert Haggar Chairman
Francois Noel Merchand Independent Director
Margareta Tanase Director & Director-Industrial Affairs